Ocular FIP treatment gains traction as antiviral evidence grows

CURRENT FULL VERSION: A VetGirl podcast on ocular FIP is drawing attention to one of the biggest changes in feline practice in recent years: a disease once viewed as nearly uniformly fatal now has increasingly evidence-backed antiviral treatment options, even for harder cases with ocular involvement. The conversation reflects a broader clinical shift toward treating FIP as a condition that may be medically managed, rather than simply confirmed and palliated, provided veterinarians can diagnose early, dose appropriately, and monitor carefully. Reported response rates in contemporary discussion and review literature are now often in the roughly 85% to 90% range, reinforcing how dramatically expectations have changed. (pubmed.ncbi.nlm.nih.gov)

That shift has been building for several years. Early GS-441524 and remdesivir studies changed expectations for FIP survival, but ocular and neurologic forms remained especially concerning because blood-eye and blood-brain penetration were less certain and these cats often needed more aggressive protocols. More recently, guideline and review literature has started to formalize what many feline-focused clinicians have been doing in practice: stratifying treatment by disease form and severity, rather than treating all FIP cases the same way. The VetGirl ocular FIP episode also emphasizes that eye disease can be a leading presentation, not just a late complication, with uveitis sometimes the dominant clinical feature. (academic.oup.com)

One important development for U.S. clinicians came on May 10, 2024, when FDA said it did not intend to enforce new animal drug approval requirements for compounded GS-441524 prescribed by a veterinarian for a specific cat with FIP under the conditions in Guidance for Industry #256. FDA also stressed that these compounded products remain unapproved drugs and are not technically “legal,” but the policy materially changed real-world prescribing access. Cornell’s Feline Health Center noted that Stokes Pharmacy, working with Bova, announced U.S. availability of compounded oral GS-441524 beginning June 1, 2024. As VetGirl notes in a separate dosing-focused podcast, that matters because remdesivir is injectable, while GS-441524 can be compounded into oral tablets through veterinary pharmacy channels. (fda.gov)

The clinical literature supports why ocular FIP is getting special attention. The VetGirl episode highlights a 2025 Royal Veterinary College observational case series evaluating remdesivir, GS-441524, or both in cats with ocular FIP. It also offers a practical refresher on what these cases can look like in the exam room: anterior segment findings may include keratic precipitates, iris color change, dyschoria or anisocoria, hyphema, hypopyon, or fibrinous exudate, while posterior segment changes can include tapetal or non-tapetal retinal lesions, retinal hemorrhage or vascular tortuosity, detachment, or perivascular cuffing. These signs may be unilateral or bilateral and can be the first clue to systemic disease. More broadly, a 2025 systematic review covering studies from 2018 to 2024 found an overall GS-441524 treatment success rate of 84.6% across 650 cases, with lower success in wet FIP and neurologic complications, and recommended dose adjustments based on severity and ocular or neurologic involvement. In a Frontiers study of 118 cats treated with GS-441524 or molnupiravir, cats with ocular or neurologic signs received higher doses than standard FIP cases, and planned treatment duration was 84 days. Meanwhile, an earlier JVIM study reported that ophthalmic changes generally improved within two to four weeks of starting antiviral therapy, but also noted that persistent abnormalities later in treatment may justify dose escalation, treatment extension, or adding a second antiviral. (pubmed.ncbi.nlm.nih.gov)

Guideline writers are also signaling that protocols are still evolving. The ABCD FIP guideline cites a prospective randomized study in cats with effusive FIP, including a small number with ocular or neurologic signs, suggesting a six-week oral GS-441524 course may be as effective as 12 weeks in selected cases. But that same body of literature doesn’t settle the question for ocular FIP broadly, where severity, concurrent neurologic disease, and drug absorption may all change the calculus. In practice, that means many veterinarians will still be cautious about shortening therapy in cats with eye involvement. That caution is echoed by a separate VetGirl review of a 2025 JSAP paper on high-dose induction therapy and treatment termination criteria, which frames a key real-world problem: cats often look better within about a week of starting antivirals, but early clinical improvement does not necessarily mean viral clearance, especially in harder-to-penetrate tissues like the eye and central nervous system. The study discussed there evaluated acute-phase proteins including serum amyloid A and alpha-1 acid glycoprotein, along with albumin:globulin ratio trends, as more objective markers to help guide when treatment might safely stop. (abcdcatsvets.org)

Diagnosis remains the other major practical challenge. VetGirl’s broader FIP update stresses that while antivirals have transformed prognosis, most cases in practice are still diagnosed presumptively rather than definitively. The podcast reviews familiar epidemiologic and clinical cues: many affected cats are young, often from multicat environments, and disease follows mutation of feline enteric coronavirus in a minority of exposed cats, with vasculitis driving the downstream signs. Ocular and neurologic involvement are more common in non-effusive disease, though overlap between wet and dry forms is common. A related Vet Blast discussion makes the same point from an internist’s perspective: treatment may be more accessible than ever, but diagnosis is still frustratingly imperfect and depends on assembling signalment, exam findings, clinicopathologic changes, imaging, and fluid analysis into a strong presumptive case. (pubmed.ncbi.nlm.nih.gov)

Expert commentary in the sourced material is limited because the VetGirl item is a podcast rather than a formal study release, but the surrounding academic and guideline literature is fairly consistent: ocular FIP is treatable, yet it’s not the place for one-size-fits-all dosing. The strongest recurring themes are early recognition, dose selection based on disease presentation, serial ophthalmic and systemic monitoring, and readiness to adjust if the cat’s clinical course stalls. That’s less a sound bite than a practical framework, but it aligns with how referral internists and feline-focused practices are approaching these cases. This last point is an inference drawn from the consistency of the guideline, review, and treatment-study literature. (pubmed.ncbi.nlm.nih.gov)

Why it matters: For general practitioners, emergency clinicians, internists, and ophthalmology teams, ocular FIP is becoming a disease that rewards faster suspicion and tighter case management. The regulatory opening around compounded GS-441524 has lowered a major access barrier in the U.S., but it also puts more responsibility on veterinarians to counsel pet parents about compounded, unapproved products, treatment expectations, monitoring intervals, and the possibility that complicated cases may need higher doses or longer courses. It also sharpens the need for practical diagnostic confidence: because FIP is often treated on a presumptive basis, clinicians need to recognize compatible ocular lesions, systemic inflammatory patterns, and signalment quickly enough to avoid losing valuable treatment time. Clinically, the message is encouraging but not casual: better outcomes are increasingly achievable, yet ocular involvement still signals a case that deserves careful follow-through. (fda.gov)

What to watch: The next phase will likely center on protocol refinement, including whether shorter courses can be safely extended beyond selected uncomplicated cases, how molnupiravir and combination therapy fit into rescue or first-line care, and whether future guidance further standardizes dosing for cats with ocular signs. U.S. regulatory policy is also worth watching, especially around compounding, office-stock access, and whether additional formal pathways emerge for FIP antivirals. Just as important, expect more discussion around objective monitoring tools such as acute-phase proteins and around how best to operationalize presumptive diagnosis in primary and referral practice, since those two issues may determine how confidently clinicians can start, adjust, and stop therapy in the real world. (abcdcatsvets.org)